Corporate ActionJun 3, 2026, 05:27 PM
Trinity Biotech Amends F-1 for 33.75M ADS Secondary Offering
AI Summary
Trinity Biotech PLC filed a Post-Effective Amendment No. 1 to its F-1 Registration Statement, registering up to 33,752,429 American Depositary Shares (ADSs) for resale by YA II PN, LTD., the Selling Securityholder. This action is pursuant to a Standby Equity Purchase Agreement allowing the company to sell up to $25 million in ADSs to the investor. While Trinity Biotech will not receive proceeds from the Selling Securityholder's resale, it may receive up to $25 million from direct sales to the investor, intended for operating expenses, working capital, and general corporate purposes. The filing also updates information to reflect fiscal year ended December 31, 2025 results and a recent debt amendment.
Key Highlights
- Trinity Biotech filed a Post-Effective Amendment No. 1 to its F-1 Registration Statement.
- The amendment registers up to 33,752,429 ADSs (representing 675,048,580 ordinary shares) for resale by YA II PN, LTD.
- The company may sell up to $25 million in ADSs to YA II PN, LTD. under a Standby Equity Purchase Agreement.
- Trinity Biotech has already sold 1,355,000 ADSs for $859,270 gross proceeds under the Purchase Agreement.
- 175,537 Commitment ADSs were issued to the investor as a structuring fee.
- Total debt as of December 31, 2025, was $124,555,000 (actual) and $130,920,000 (as adjusted).
- Cash and cash equivalents as of December 31, 2025, were $5,138,000 (actual) and $7,638,000 (as adjusted).
- ADSs trade on Nasdaq under "TRIB"; closing price on June 2, 2026, was $0.7321.
Price Impact
More from TRIB